Profile: Allon Therapeutics Inc (NPC.TO)

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Its davunetide intranasal (AL-108), has demonstrated human efficacy in amnestic mild cognitive impairment (aMCI). The Company has Phase II human efficacy programs pursuing underserved markets, including Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company’s compounds are derived from two technology platforms, activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF). The Company’s clinical compounds, davunetide intranasal (AL-108) and davunetide intravenous (AL-208), are both derived from the ADNP platform. Pre-clinical compound AL-309 is derived from the ADNF platform. In addition to its clinical programs, davunetide intranasal and davunetide intravenous, the Company has additional neuroprotective pre-clinical drug candidates from the ADNP and ADNF platforms.